Last reviewed · How we verify
during one week for the active treatments
The drug, currently marketed by Assistance Publique - Hôpitaux de Paris, holds a position in the market with its key composition patent expiring in 2028. A key strength of the drug is its established presence in the market, leveraging the credibility and resources of Assistance Publique - Hôpitaux de Paris. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | during one week for the active treatments |
|---|---|
| Also known as | Amoxicillin, Clarythromycin or metronidazole, Pantoprazole, Placebo |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- FAP-targeted PET/NIR in Lung Malignant Tumors
- SIESTA: Sleep Intervention to Enhance Cognitive Status and Reduce Beta Amyloid (NA)
- Dyad Plus Effectiveness/Feasibility (NA)
- Safety and Effectiveness of the BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for Treatment of Alcohol Use Disorder (AUD) (NA)
- Trial to Test the Effectiveness of Vibrotactile Stimulation for Lower Limb Spasticity (NA)
- Comparison of ESWT and Deep Tissue Massage in Individuals With Medial Tibial Stress Syndrome (NA)
- Remote Monitoring for Equity in Advancing Control of Hypertension (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: